25-OH Vitamin D: Sex- and Cycle-Related Differences in Normal and Optimal Ranges

Why a Single Reference Range Is Not Enough

The laboratory reference interval printed on most reports, typically 30 to 100 ng/mL, was derived from population medians that pool men and women, reproductive-age adults with post-menopausal adults, and unsupplemented people with those on hormonal therapies. That pooling obscures real biology. Sex hormones regulate vitamin D metabolism at several enzymatic steps, and the clinical consequences of getting those levels wrong, including bone loss, immune dysregulation, and mood instability, differ meaningfully between sexes and across the reproductive lifespan.

The Endocrine Society's 2011 clinical practice guideline defines deficiency as 25-OH vitamin D <20 ng/mL and insufficiency as 20 to 29 ng/mL, while acknowledging that optimal targets for specific populations may be higher. [1] Understanding where your patient sits relative to their physiologic context, not just a lab printout, is what drives good clinical decisions.

How Vitamin D Is Metabolized

Dietary and skin-synthesized vitamin D3 (cholecalciferol) travels to the liver, where CYP2R1 converts it to 25-OH vitamin D, the storage and transport form measured in serum. A second hydroxylation by renal CYP27B1 (1-alpha-hydroxylase) produces the active hormone 1,25-dihydroxyvitamin D (calcitriol). Sex hormones modulate both CYP2R1 expression in the liver and CYP27B1 activity in the kidney. That dual-site regulation is why serum 25-OH vitamin D levels change with hormonal shifts even when vitamin D intake stays constant. [2]

What the Assay Measures

Serum 25-OH vitamin D captures the sum of D2 and D3 metabolites and reflects weeks-to-months of vitamin D status, unlike the active calcitriol form which fluctuates hour to hour. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the reference method; immunoassays can underestimate levels by 5 to 15% in some commercial kits, which matters most when interpreting borderline results near the 30 ng/mL cutoff. [3]

Sex Differences in 25-OH Vitamin D Levels

Men and women show consistent differences in 25-OH vitamin D even after controlling for sun exposure, dietary intake, and body mass index. NHANES 2001 to 2006 data (N=20,289) found that women aged 20 to 39 had mean serum 25-OH vitamin D levels approximately 3 to 4 ng/mL lower than age-matched men, a difference that partly reversed after menopause. [4]

Why Men Tend Toward Higher Levels in Reproductive Years

Testosterone appears to upregulate hepatic CYP2R1 activity, increasing the efficiency of the first hydroxylation step. In a 2012 cross-sectional analysis published in the European Journal of Endocrinology, free testosterone correlated positively with 25-OH vitamin D (r=0.31, P<0.001) in 1,362 community-dwelling men after adjusting for age, BMI, and season. [5] This does not mean testosterone supplementation is a vitamin D strategy, but it does mean that hypogonadal men may be biochemically disadvantaged at the conversion step and should have vitamin D checked as part of any testosterone workup.

Why Pre-Menopausal Women Run Lower

Estradiol has a more complex effect. At physiologic concentrations it mildly suppresses renal CYP27B1, which through a feedback loop can slightly reduce the conversion pressure on the hepatic step and result in lower 25-OH vitamin D accumulation. Higher body fat percentage in women, and the preferential partitioning of fat-soluble vitamin D into adipose tissue, further reduces circulating levels. [6]

After menopause, the estradiol withdrawal appears to partially reverse this suppression. Post-menopausal women, however, also lose estrogen's protective effect on bone, which makes achieving 40 to 50 ng/mL even more clinically relevant in that demographic. The 2020 USPSTF recommendation statement on vitamin D supplementation for cancer prevention notes that the evidence base is insufficient for a blanket supplementation recommendation but does not contradict targeting sufficiency in high-risk groups. [7]

Oral Contraceptives and 25-OH Vitamin D

Combined oral contraceptives (COCs) containing ethinyl estradiol reliably raise 25-OH vitamin D levels. This is one of the best-documented hormone-vitamin D interactions in the literature.

Magnitude of the Effect

A 2012 cross-sectional study by Grundmann and von Versen-Höynck (N=1,659) found that COC users had mean 25-OH vitamin D levels 20.4% higher than non-users (40.2 vs. 33.4 ng/mL, P<0.001) after adjusting for season, skin type, and dietary intake. [8] The mechanism is an estrogen-driven increase in the serum vitamin D-binding protein (DBP), which raises total (bound) 25-OH vitamin D without necessarily raising the free, bioavailable fraction proportionally.

Clinical Interpretation Caveat

When a patient starts or stops COCs, the reported 25-OH vitamin D level will shift by 15 to 25% even if actual tissue vitamin D status is unchanged. Retesting 8 to 12 weeks after initiating or discontinuing a COC allows the DBP to stabilize before interpreting the result. Ordering a free 25-OH vitamin D level alongside total 25-OH vitamin D can clarify whether the change is DBP-driven or reflects genuine status change, though free assays add cost and are not yet widely standardized. [9]

Menstrual Cycle Phase and Short-Term Variation

Within a single menstrual cycle, 25-OH vitamin D shows modest but measurable fluctuation. A prospective study by Lasco et al. (2012, N=40) tracked serum 25-OH vitamin D at the follicular phase, mid-cycle, and luteal phase in healthy pre-menopausal women. Levels were approximately 2 to 3 ng/mL lower in the late luteal phase compared with the follicular phase, a difference below clinical decision thresholds but relevant for serial monitoring in research or high-frequency clinical contexts. [10]

Practical Implication for Serial Testing

For routine clinical management, cycle-phase-driven variation is small enough that standardizing the draw to a specific cycle day is not necessary. However, if a patient reports consistent late-luteal symptoms, including low mood, fatigue, or musculoskeletal aching, that are temporally linked and her 25-OH vitamin D is borderline (28 to 34 ng/mL), targeting the upper end of the sufficiency range (50 to 60 ng/mL) provides a reasonable buffer against the luteal trough.

Pregnancy, Lactation, and Postpartum

Vitamin D requirements increase substantially in pregnancy. Placental CYP27B1 expression is high; the fetus relies entirely on maternal 25-OH vitamin D for bone mineralization, immune programming, and neurodevelopment.

Target During Pregnancy

The widely cited Hollis and Wagner RCT (2011, N=350) randomized pregnant women to 400, 2,000, or 4,000 IU/day of vitamin D3 from 12 to 16 weeks until delivery. Women in the 4,000 IU group reached mean 25-OH vitamin D of 46 ng/mL and had significantly fewer adverse outcomes including preeclampsia and preterm birth compared with the 400 IU group (P<0.05), with no cases of toxicity. [11] The authors concluded that a maternal target of at least 40 ng/mL is needed to sustain adequate fetal transfer.

The American College of Obstetricians and Gynecologists currently recommends testing 25-OH vitamin D in pregnancy when risk factors are present and treating deficiency with supplemental vitamin D3, though a universal dosing recommendation above 1,000 to 2,000 IU/day has not yet been formally adopted. [12]

Lactation

Breast milk is a poor source of vitamin D regardless of maternal status. An exclusively breastfed infant whose mother has 25-OH vitamin D of 40 ng/mL will still receive inadequate vitamin D through milk. The AAP recommends 400 IU/day supplemental D3 for all breastfed infants, separate from maternal supplementation strategy. Postpartum, maternal 25-OH vitamin D levels typically drop 5 to 10 ng/mL within the first 3 months if supplementation is not maintained. [13]

Hormone Replacement Therapy (HRT) in Peri- and Post-Menopause

The interaction between exogenous estrogen and vitamin D metabolism at menopause has direct clinical significance for bone protection.

Oral vs. Transdermal HRT

Oral estradiol preparations, like COCs, increase hepatic DBP production and raise total 25-OH vitamin D, often by 10 to 18%. Transdermal estradiol bypasses hepatic first-pass metabolism and has a smaller effect on DBP, meaning the apparent rise in 25-OH vitamin D is less pronounced on transdermal routes. [14]

For a patient switching from oral to transdermal HRT, a drop in reported 25-OH vitamin D does not automatically indicate worsening status. Free 25-OH vitamin D may be essentially unchanged. Clinicians should not reflexively increase vitamin D supplementation in response to that lab shift without also reviewing symptoms, bone density trends, and supplementation history.

Bone Protection Threshold in Post-Menopause

The Women's Health Initiative Calcium and Vitamin D trial (WHI CaD, N=36,282) found that 1,000 mg calcium plus 400 IU vitamin D3 daily modestly reduced hip fracture risk in post-menopausal women not already supplementing (hazard ratio 0.71, P=0.046 in the compliant subgroup). [15] The 400 IU dose used in WHI CaD is now widely considered inadequate for achieving or maintaining 40+ ng/mL targets. Most post-menopausal women on HRT with a baseline 25-OH vitamin D of 25 to 35 ng/mL will need 2,000 to 4,000 IU/day of D3 to reliably reach 40 to 50 ng/mL, adjusted by body weight and baseline level. [1]

Testosterone Replacement Therapy (TRT) and 25-OH Vitamin D

Men starting TRT often have low baseline 25-OH vitamin D, partly because hypogonadism and vitamin D deficiency share common risk factors (obesity, sedentary lifestyle, poor dietary quality). Whether TRT independently raises 25-OH vitamin D remains debated.

Evidence From Intervention Studies

A 2012 RCT by Pilz et al. (N=54) showed that testosterone supplementation in vitamin D-deficient hypogonadal men raised 25-OH vitamin D by a mean of 6.5 ng/mL over 12 months compared with placebo (P=0.03), an effect attributed to androgen upregulation of hepatic 25-hydroxylase activity. [16] The effect size is modest and would not replace direct vitamin D supplementation in a deficient man on TRT, but it does support measuring 25-OH vitamin D at TRT baseline and again at 3 to 6 months.

Practical TRT Protocol Recommendation

Check 25-OH vitamin D at TRT initiation. If <30 ng/mL, load with 5,000 IU/day D3 for 8 weeks, then drop to 2,000 to 3,000 IU/day maintenance. Recheck at the 12-week TRT follow-up visit. Target 40 to 60 ng/mL. Magnesium glycinate 200 to 400 mg/day should be co-administered because magnesium is a cofactor for both CYP2R1 and CYP27B1 and deficiency blunts the response to supplementation. [17]

Defining "Normal" vs. "Optimal" for 25-OH Vitamin D

The distinction between "not deficient" and "optimally replete" matters for clinical practice.

Society-Defined Thresholds

The Endocrine Society defines sufficiency as 25-OH vitamin D >30 ng/mL based on parathyroid hormone (PTH) suppression data. [1] The Institute of Medicine (now National Academy of Medicine) set a more conservative threshold of 20 ng/mL for bone health in the general population. [18] These thresholds address prevention of classic deficiency disease, not optimization of immune function, mood regulation, or cancer risk reduction.

Longevity-Medicine and Functional Targets

A 2014 meta-analysis by Garland et al. In Anticancer Research analyzed 32 studies and found that 25-OH vitamin D levels of 40 to 60 ng/mL were associated with the lowest all-cause mortality and colorectal cancer incidence. [19] A 2022 analysis of the VITAL trial (N=25,871, median follow-up 5.3 years) found that vitamin D3 2,000 IU/day reduced cancer mortality by 17% overall, with stronger effects in participants with BMI <25 and those who had been supplementing for >2 years. [20]

Longevity-medicine consensus, though not yet a formal society guideline, generally targets 40 to 60 ng/mL for adults without hypercalcemic conditions. Levels above 80 ng/mL carry increased risk of hypercalciuria and soft-tissue calcification; levels above 100 ng/mL define toxicity risk. [1]

Sex-Specific Targets Summary

The following targets represent the HealthRX clinical framework for 25-OH vitamin D interpretation by sex and hormonal context, synthesized from the primary literature cited throughout this article:

| Population | Minimum Sufficiency | Functional Target | Retest After Dose Change | |---|---|---|---| | Adult men (eugonadal) | 30 ng/mL | 40 to 50 ng/mL | 8 to 12 weeks | | Adult men on TRT | 30 ng/mL | 45 to 60 ng/mL | 12 weeks | | Pre-menopausal women (no COC) | 30 ng/mL | 40 to 50 ng/mL | 8 to 12 weeks | | Women on COC | 35 ng/mL (adjust for DBP effect) | 45 to 55 ng/mL free-equivalent | 12 weeks after COC change | | Pregnant women | 40 ng/mL | 40 to 60 ng/mL | Every trimester | | Post-menopausal women (no HRT) | 40 ng/mL | 50 to 60 ng/mL | 8 to 12 weeks | | Post-menopausal women on oral HRT | 35 ng/mL (adjust for DBP) | 45 to 55 ng/mL | 12 weeks after HRT change |

Supplementation Dosing by Starting Level

Dose requirements are non-linear. A person at 15 ng/mL needs far more than twice the dose of someone at 28 ng/mL to reach 50 ng/mL, because adipose sequestration and repletion kinetics differ at severely depleted states. Body weight also matters: each 1,000 IU/day of D3 raises 25-OH vitamin D by approximately 6 to 10 ng/mL in a 70 kg adult but only 4 to 7 ng/mL in a 100 kg adult. [21]

Loading vs. Maintenance

For adults with 25-OH vitamin D <20 ng/mL, a loading strategy of 50,000 IU D3 once weekly for 8 weeks, followed by 2,000 to 4,000 IU/day maintenance, achieves the sufficiency threshold faster than daily dosing alone. The Endocrine Society supports this approach for confirmed deficiency. [1] Weekly high-dose D2 (ergocalciferol) is less effective than D3 at raising and sustaining 25-OH vitamin D, as confirmed in a 2012 head-to-head RCT by Heaney et al. [22]

Co-Factors

Vitamin D3 without adequate cofactors under-performs. Magnesium activates both hydroxylation enzymes. Vitamin K2 (MK-7, 100 to 200 mcg/day) directs calcium to bone rather than arterial walls, which matters at higher D3 doses. These are not optional additions for patients targeting 50+ ng/mL. [17]

When to Test and How to Interpret

Test 25-OH vitamin D at baseline in any patient presenting with fatigue, bone pain, frequent infections, mood instability, or suboptimal response to TRT or HRT. Retest 8 to 12 weeks after any supplementation change, or 12 weeks after initiating or changing hormonal therapy.

Confounders to Document

• Season and latitude (northern latitudes in winter can drop levels 10 to 15 ng/mL below summer values)
• Recent tanning bed use or sun exposure change
• New medications: antiepileptics (phenytoin, carbamazepine), glucocorticoids, and rifampin all accelerate vitamin D catabolism via CYP3A4 induction [2]
• BMI change >5 kg (adipose partitioning changes)
• COC start or stop within the prior 12 weeks

Assay Selection

Request 25-OH vitamin D total (D2 + D3) by LC-MS/MS when available. If the clinical decision hinges on a borderline result between 28 to 35 ng/mL, also request free 25-OH vitamin D, particularly in patients with suspected DBP elevation (oral estrogen users, pregnancy, hepatic disease) or DBP genetic variants common in Black populations. [3]

A 25-OH vitamin D result of 32 ng/mL in a woman on oral ethinyl estradiol may reflect a free fraction closer to 26 ng/mL once DBP is accounted for. That distinction changes the supplementation recommendation.